• PDF / 170,140 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 59 Downloads / 139 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 4 case reports In a retrospective, single-center, single-arm, observational study of 45 patients (study period: September 2012 to August 2019), 4 patients [ages and sexes not stated] were described, who developed anaemia (1 patient), leucopenia (1 patient), low neutrophil levels (1 patient) and chest pain (1 patient) during treatment with capecitabine or lutetium-(177lu)-oxodotreotide [177Lu-DOTATATE] for neuroendocrine tumour (NTE) [durations of treatments to reactions onsets not stated; not all doses and outcomes stated]. The patients, who had NTE, started receiving cyclic IV infusion of lutetium-(177lu)-oxodotreotide over 30 mins per cycle at 8–12 weeks interval up to 4 cycles. Additionally, the patients received cyclic low-dose oral capecitabine at a dose of 1250 mg/m2 per day from days 0 to 14 of each lutetium-(177lu)-oxodotreotide cycle. The patients received pretreatment with ondansetron as antiemetic and dexamethasone as corticosteroid. Additionally, the patients received nephroprotection prophylaxis with adequate hydration, lysine hydrochloride [lysine] and arginine. Subsequently, of the 4 patients, one patient developed grade 3/4 anaemia and another developed grade 3/4 laeucopenia as a toxicity of lutetium-(177lu)-oxodotreotide and capecitabine. The third patient experienced persistently low neutrophil levels until 6months after the second cycle of lutetium-(177lu)-oxodotreotide and capecitabine as their side effect, leading to discontinuation of further treatment cycles of lutetium-(177lu)-oxodotreotide and capecitabine. However, this patient died 12 months later [cause of death not stated]. The fourth patient developed adverse effect specific for capecitabine in the form of transient mild grade 1 chest pain. Satapathy S, et al. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors. Clinical Nuclear 803517609 Medicine 45: e393-e399, No. 9, Sep 2020. Available from: URL: http://doi.org/10.1097/RLU.0000000000003170

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832